Home › Funds › Palo Alto Investors LP › CLDX
Palo Alto Investors LP position in CLDX
CELLDEX THERAPEUTICS INC NEW · Health Care
Palo Alto Investors LP reported holding 343,101 shares of CLDX (CELLDEX THERAPEUTICS INC NEW) in its Q3 2026 13F filing — a position valued at US$11.1M, representing 1.65% of its reported portfolio and ranking #18 among its reported holdings. Palo Alto Investors LP has disclosed CLDX holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Palo Alto Investors LP's CLDX position evolved
Palo Alto Investors LP first disclosed a stake in CLDX in Q1 2026 at 296,408 shares (US$9.4M). The position peaked in Q2 2026 at 399,856 shares, worth US$14.9M. Across 3 filings, Palo Alto Investors LP increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 343,101 shares valued at US$11.1M — a reduction of -56,755 shares quarter over quarter.. Notable position changes include a 35% increase in Q2 2026 (shares fell 13% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 296.41K | $9.40M | New |
| Q2 2026 | 399.86K | $14.88M | Add |
| Q3 2026 | 343.10K | $11.12M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CLDX and 13F data
CLDX (CELLDEX THERAPEUTICS INC NEW) is a Health Care company. 36 other funds we track also report a position in CLDX — the largest reported positions include Kynam Capital Management, LP (US$164.2M), BAKER BROS. ADVISORS LP (US$83.1M), Deep Track Capital, LP (US$68.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CLDX
- Kynam Capital Management, LP 5.07M sh · $164.19M · Q3 2026
- BAKER BROS. ADVISORS LP 2.56M sh · $83.13M · Q3 2026
- Deep Track Capital, LP 2.13M sh · $68.89M · Q3 2026
- EVENTIDE ASSET MANAGEMENT, LLC 1.90M sh · $61.46M · Q3 2026
- Eversept Partners, LP 1.17M sh · $38.07M · Q3 2026
- Affinity Asset Advisors, LLC 1.16M sh · $37.61M · Q3 2026
- Elmind Capital, LP 1.11M sh · $35.98M · Q3 2026
- Commodore Capital LP 1.00M sh · $32.41M · Q3 2026
- Novo Holdings A/S 950.00K sh · $30.79M · Q3 2026
- Frazier Life Sciences Management, L.P. 900.08K sh · $29.17M · Q3 2026
- ADAR1 Capital Management, LLC 799.30K sh · $25.91M · Q3 2026
- Trails Edge Capital Partners, LP 765.00K sh · $24.79M · Q3 2026
More on Palo Alto Investors LP
FAQ
How long has Palo Alto Investors LP held CLDX?
Palo Alto Investors LP has disclosed CLDX holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Palo Alto Investors LP's current position in CLDX?
As of Q3 2026, Palo Alto Investors LP holds 343.10K shares of CLDX (CELLDEX THERAPEUTICS INC NEW), valued at $11.12M, representing 1.65% of its reported portfolio and ranking #18.
Has Palo Alto Investors LP been buying or selling CLDX?
In the latest 13F filing (Q3 2026), Palo Alto Investors LP reduced its position in CLDX. The position peaked in Q2 2026 at 399.86K shares.
Which other funds hold CLDX?
Other major institutional holders of CLDX include Kynam Capital Management, LP, BAKER BROS. ADVISORS LP, Deep Track Capital, LP, among 36 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.